Inflammatory Bowel Disease Therapy
Researchers from Friedrich-Schiller University report recent findings in inflammatory bowel disease therapy
Published in Gastroenterology Week, April 19th, 2010
New research, 'Adverse effects of biologics used for treating IBD,' is the subject of a report. According to recent research from Jena, Germany, "In the last decade, biologic agents, in particular anti-TNF agents such as infliximab, adalimumab, and certolizumab have substantially extended the therapeutic armamentarium of inflammatory bowel disease (IBD). Additional approaches include biologicals, such as natalizumab, that block leucocyte adhesion; those that target cytokines, such as interleukin-12/23 antibodies; or those that inhibit T-cell signaling, such as interleukin-6 receptor antibodies."
"However, these drugs have a number of contraindications and side effects,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gastroenterology Week
More Articles from Gastroenterology Week
- JAMA and Archives Journals
Study finds no evidence that obese patients are less likely to receive recommended care - Journal of the National Cancer Institute
Blacks have lower follow-up rates after colon cancer screening - Porter Novelli
Novel soy germ-based dietary supplement, SE5-OH containing natural S-Equol, examined for safety and influence on hormones in pre- and post-menopausal women - Saint Louis University
New hope for treating hepatitis C: Telaprevir - University of California - Davis
New study may explain how weight-loss surgery reverses type 2 diabetes - American College of Gastroenterology
Rome Foundation Introduces New Clinical Tool for Diagnosis of Functional Gastrointestinal Disorders in the American Journal of Gastroenterology - More from this issue of Gastroenterology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
